This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakaoka, H. Articles by Yamaji, T. Search for Related Content PubMed PubMed Citation Articles by Nakaoka, H. Articles by Yamaji, T.

Hypertension, Vol 10, 221-225, Copyright © 1987 by American Heart Association

ARTICLES

Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension

H Nakaoka, Y Kitahara, M Amano, K Imataka, J Fujii, M Ishibashi and T Yamaji

Plasma levels of atrial natriuretic peptide (ANP) were measured in 32 untreated subjects with essential hypertension and in 31 patients undergoing long-term treatment with beta-blockers. Patients receiving beta-blockers had significantly higher mean plasma ANP levels (72.0 +/- 36.0 [SD] pg/ml) than did untreated hypertensive subjects (39.8 +/- 15.8 pg/ml; p less than 0.01) and healthy normotensive controls (33.9 +/- 16.6 pg/ml; n = 61, p less than 0.01), while the mean plasma ANP concentration in untreated hypertensive subjects was not statistically different from that in control subjects. Administration of atenolol, 50 mg/day, for 4 weeks to 10 untreated subjects resulted in a significant (p less than 0.001) rise in plasma ANP levels (from 38.8 +/- 9.5 to 68.7 +/- 20.6 pg/ml). In 31 patients undergoing long-term treatment with beta-blockers, multivariate regression analysis revealed that age, pretreatment mean blood pressure, and plasma concentration of cyclic 3',5'-guanosine monophosphate (cGMP) were significant predictors of plasma ANP levels. These results suggest that beta-adrenergic receptor blockade in patients with essential hypertension elevates plasma ANP levels with a concomitant rise in cGMP concentrations, and that increased ANP in plasma may play a role in the compensatory mechanism that operates in response to beta-adrenergic receptor blockade.

This article has been cited by other articles:

				M. S. Kallistratos, A. Dritsas, I. D. Laoutaris, and D. V. Cokkinos N-terminal Prohormone Brain Natriuretic Peptide Plasma Levels in Heart Failure Are Affected Both Directly and Indirectly by Carvedilol Angiology, July 1, 2008; 59(3): 323 - 328. [Abstract] [PDF]

				M. E. Davis, A. M. Richards, M. G. Nicholls, T. G. Yandle, C. M. Frampton, and R. W. Troughton Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure Circulation, February 21, 2006; 113(7): 977 - 985. [Abstract] [Full Text] [PDF]

				A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]

				A Luchner and H Schunkert Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system Cardiovasc Res, August 15, 2004; 63(3): 443 - 449. [Abstract] [Full Text] [PDF]

				F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, J. Trawinski, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy Eur J Heart Fail, March 15, 2004; 6(3): 343 - 350. [Abstract] [Full Text] [PDF]

				Y. Hirata, A. Matsumoto, T. Aoyagi, K. Yamaoki, I. Komuro, T. Suzuki, T. Ashida, T. Sugiyama, Y. Hada, I. Kuwajima, et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload Cardiovasc Res, August 15, 2001; 51(3): 585 - 591. [Abstract] [Full Text] [PDF]

				A. M. Richards, R. Doughty, M. G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E. A. Espiner, C. Frampton, and T. G. Yandle Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction Circulation, February 16, 1999; 99(6): 786 - 792. [Abstract] [Full Text] [PDF]

				A. Luchner, J. C. Burnett Jr., M. Jougasaki, H.-W. Hense, G.u. A. J. Riegger, and H. Schunkert Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1839 - 1844. [Abstract] [Full Text] [PDF]

				T. Yoshimoto, M. Naruse, A. Tanabe, K. Naruse, T. Seki, T. Imaki, T. Muraki, Y. Matsuda, and H. Demura Potentiation of Natriuretic Peptide Action by the {beta}-Adrenergic Blocker Carvedilol in Hypertensive Rats: A New Antihypertensive Mechanism Endocrinology, January 1, 1998; 139(1): 81 - 88. [Abstract] [Full Text] [PDF]

				V. M. Campese, M. Tawadrous, R. Bigazzi, S. Bianchi, A. S. Mann, S. Oparil, and L. Raij Salt Intake and Plasma Atrial Natriuretic Peptide and Nitric Oxide in Hypertension Hypertension, September 1, 1996; 28(3): 335 - 340. [Abstract] [Full Text]

				J. Hama, S. Nagata, T. Takenaka, H. Kino, K. Kamoi, S. Shimada, M. Horiuchi, and R. Katori Atrial Natriuretic Peptide and Antihypertensive Action Due to {beta}-Blockade in Essential Hypertensive Patients Angiology, June 1, 1995; 46(6): 511 - 516. [Abstract] [PDF]